Information on the total number of voting rights and shares
In accordance with article 15 of the Act of 2nd May 2007 on the disclosure of large shareholdings, Nyxoah S.A. publishes the below information following the issue of 23,500 new shares on 28 October 2020 pursuant to the exercise of warrants
Share capital: EUR 3,796,047.64
Total number of securities carrying voting rights: 22,097,609 (all ordinary shares)
Total number of voting rights (= denominator): 22,097,609 (all relating to ordinary shares)
Number of rights to subscribe to securities carrying voting rights not yet issued:
161 “2013 ESOP Warrants” issued on 3 May 2013 and 23 December 2014, entitling their holders to subscribe for a total number of 80,500 securities carrying voting rights (all ordinary shares);
435 “2016 ESOP Warrants” issued on 3 November 2016, entitling their holders to subscribe for a total number of 217,500 securities carrying voting rights (all ordinary shares);
319 “2018 ESOP Warrants” issued on 12 December 2018, entitling their holders to subscribe for a total number of 159,500 securities carrying voting rights (all ordinary shares); and
550,000 “2020 ESOP Warrants” issued on 21 February 2020, entitling their holders to subscribe for a total number of 550,000 securities carrying voting rights (all ordinary shares).
- ENDS -
For further information, please contact:
Rémi Renard, VP Therapy Development and Education
+32 472 12 64 40
For media enquiries, please contact:
Consilium Strategic Communications
Amber Fennell, Ashley Tapp, Lindsey Neville, Taiana De Ruyck Soares
+44 (0)20 3709 5700
Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a CE-Mark validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.
Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit www.nyxoah.com.
Caution – CE marked since 2019. Investigational device in the United States. Limited by federal law to investigational use.
1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.